



# J-code availability brochure

## INDICATION AND USAGE

LYNOZYFIC is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

## IMPORTANT SAFETY INFORMATION

### **WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME**

- Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Initiate treatment with LYNOZYFIC step-up dosing to reduce the risk of CRS. Manage CRS, withhold LYNOZYFIC until CRS resolves, and modify the next dose or permanently discontinue based on severity.
- Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS during treatment. Manage neurologic toxicity, including ICANS, withhold LYNOZYFIC until neurologic toxicity, including ICANS resolves, and modify the next dose or permanently discontinue based on severity.
- Because of the risk of CRS and neurologic toxicity, including ICANS, LYNOZYFIC is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the LYNOZYFIC REMS.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#), including Boxed WARNING, for LYNOZYFIC.

## The Centers for Medicare & Medicaid Services (CMS) update

The CMS announced the assignment of a product-specific J-code in the hospital outpatient setting under Medicare for LYNOZYFIC intravenous infusion.

Effective April 1, 2026, the following J-code can be used for administrative and billing purposes specific to LYNOZYFIC:

# J9601

**Injection, linvoseltamab-gcpt, 1 mg**

LYNOZYFIC is billed in 1-mg units, per its HCPCS code.

Five units are billed for the 5-mg dose; 200 units are billed for the full 200-mg dose.

Please ensure your systems are updated with this new information for the hospital outpatient setting.

The billing and coding information discussed in this guide is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed herein may not apply to all patients or to all health plans. Conversely, additional codes not listed in this guide may apply to some patients. Providers should follow payer-specific coding requirements and exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient. Information provided in this guide is effective as of April 2026.

LYNOZYFIC is only available through a restricted distribution program, LYNOZYFIC Risk Evaluation and Mitigation Strategy (REMS). Please see the [REMS Fact Sheet](#) and visit [LYNOZYFICREMS.com](#) for more information and to enroll.

HCPCS=Healthcare Common Procedure Coding System.

## IMPORTANT SAFETY INFORMATION (cont'd)

### Warnings and Precautions

**Cytokine Release Syndrome (CRS):** LYNOZYFIC can cause CRS, which can be serious or life-threatening. In LINKER-MM1, CRS occurred in 46% (54/117) of patients who received LYNOZYFIC at the recommended dose, with Grade 1 CRS occurring in 35% (41/117) of patients, Grade 2 in 10% (12/117), and Grade 3 in 0.9% (1/117). Thirty-eight percent (45/117) of patients had CRS following step-up dose 1, including 1 patient who experienced Grade 3 CRS; 8% (9/117) had an initial CRS event following a subsequent dose. Seventeen percent (19/113) of patients developed CRS after step-up dose 2, 10% (11/111) developed CRS after the first full 200-mg dose of LYNOZYFIC, and 3.6% (4/110) developed CRS after the second full dose. Recurrent CRS occurred in 20% (23/117) of patients. The median time to onset of CRS from the end of infusion was 11 (range: -1 to 184) hours after the most recent dose, with a median duration of 15 (range: 1 to 76) hours.

Clinical signs and symptoms of CRS included, but were not limited to pyrexia, chills, hypoxia, tachycardia, and hypotension. Administer pretreatment medications and initiate therapy according to LYNOZYFIC step-up dosing to reduce the incidence and severity of CRS. Monitor patients for signs and symptoms of CRS after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold LYNOZYFIC until CRS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity.

#### Infusion Related Reactions

Infusion-related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. In the patients who were treated with the recommended step-up dosing regimen and pretreatment medications, the rate of IRR was 9% [11/117 including Grade 2 IRR (4.3%) and Grade 3 IRR (1.7%)]. For IRR, interrupt or slow the rate of infusion or permanently discontinue LYNOZYFIC based on severity of reaction.

Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#), including **Boxed WARNING**, for LYNOZYFIC.

## Dosage forms and strengths

LYNOZYFIC is supplied in either a 5 mg/2.5 mL (2 mg/mL) single-dose vial or a 200 mg/10 mL (20 mg/mL) single-dose vial



LYNOZYFIC dose (mg/mL)	Vial cap color	NDC
5 mg/2.5 mL	White	61755005401
200 mg/10 mL	Blue	61755005601

**Note:** The product's NDC has been "zero-filled" to ensure creation of an 11-digit code that meets general billing standards. The zero-fill location is indicated in bold above.

This material is provided for informational purposes only, is subject to change, and should not be construed as legal or medical advice. This information may not apply to all patients or to all health plans; providers should exercise independent judgment when submitting claims.

## Recommended dosage

The recommended dosage for LYNOZYFIC is presented below. In patients who experience CRS, ICANS, or neurologic adverse reactions, refer to the approved Prescribing Information for information on management of adverse reactions and recommendations regarding administration of the next LYNOZYFIC dose. Treatment may be continued until disease progression or unacceptable toxicity.

Premedicate and follow the LYNOZYFIC step-up dosing schedule to reduce the risk of CRS and IRR. Due to the risk of CRS and neurologic toxicity, including ICANS, patients should be hospitalized for 24 hours after the first and second step-up doses.

QW dosing					Q2W dosing	Q4W dosing if ≥VGPR at or after Week 24 and ≥17 full doses
Step-up dose 1 (Day 1)	Step-up dose 2 (Day 8)	Full dose 1 (Day 15)	Full dose 2 (Week 4)	Weeks 5-13*	At Week 14 and every 2 weeks thereafter	At Week 24 or after and every 4 weeks thereafter
40 mg	40 mg	40 mg	10 mg if no prior CRS and/or IRR; 40 mg if prior CRS and/or IRR <sup>†</sup>	Pretreatment medications may be discontinued once a treatment dose of LYNOZYFIC is tolerated without CRS and/or IRR following pretreatment with 10 mg dexamethasone (or equivalent), acetaminophen (or equivalent), and diphenhydramine (or equivalent) as described.		
<b>1 to 3 hours prior to infusion:</b> Dexamethasone (or equivalent) IV						
<b>30 to 60 minutes prior to infusion:</b> • Acetaminophen (or equivalent) 650 mg to 1000 mg orally • Diphenhydramine (or equivalent) 25 mg orally or IV						
5 mg	25 mg	200 mg	200 mg	200 mg	200 mg	200 mg
4-hr infusion			1-hr infusion if tolerated <sup>‡</sup>	30-min infusion if tolerated		

\*Weekly doses should be at least 5 days apart. Biweekly doses should be at least 10 days apart. Every-4-week doses should be at least 24 days apart.

<sup>†</sup>Once full dose is tolerated without CRS and/or IRR with 40 mg dexamethasone IV, administer 10 mg dexamethasone IV and other pretreatment medications as described above until full dose is tolerated without CRS and/or IRR.

<sup>‡</sup>For patients who experienced CRS with the previous dose of LYNOZYFIC, the duration of infusion should be maintained at the duration of the previous infusion; reduce the duration of infusion sequentially in subsequent doses in patients who do not experience CRS (eg, 4 hours, 1 hour, then 30 minutes).

CRS=cytokine release syndrome; ICANS=immune effector cell-associated neurotoxicity syndrome; IRR=infusion-related reactions; IV=intravenous; NDC=National Drug Code; QW=weekly; Q2W=every 2 weeks; Q4W=every 4 weeks.

## IMPORTANT SAFETY INFORMATION (cont'd)

### Warnings and Precautions (cont'd)

**Neurologic Toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome:** LYNOZYFIC can cause serious or life-threatening neurologic toxicity, including ICANS. In LINKER-MM1, neurologic toxicity occurred in 54% of patients, with Grade 3 or 4 neurologic toxicity occurring in 8%, at the recommended dose. Neurologic toxicities included ICANS, depressed level of consciousness, encephalopathy, and toxic encephalopathy. ICANS occurred in 8% of patients who received LYNOZYFIC with the recommended dosing regimen, including Grade 3 events in 2.6%. Most patients experienced ICANS following step-up dose 1 (5%). Two patients (1.8%) experienced initial ICANS following step-up dose 2 and one patient developed the first occurrence of ICANS following a subsequent full dose of LYNOZYFIC. Recurrent ICANS occurred in one patient. The median time to onset of ICANS was 1 (range: 1 to 4) day after the most recent dose with a median duration of 2 (range: 1 to 11) days. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.

The most common clinical signs and symptoms of ICANS are confusion, depressed level of consciousness, and lethargy. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate the patient; provide supportive therapy and consider further management per current practice guidelines. Withhold LYNOZYFIC until ICANS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity. Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity, including ICANS occur at any time.

Due to the potential for neurologic toxicity, including ICANS, patients receiving LYNOZYFIC are at risk of confusion and depressed consciousness. Advise patients to refrain from driving, or operating heavy or potentially dangerous machinery, for 48 hours after completion of each of the step-up doses and in the event of new onset of any neurological symptoms, until symptoms resolve.

**LYNOZYFIC REMS:** LYNOZYFIC is available only through a restricted program under a REMS called the LYNOZYFIC REMS because of the risks of CRS and neurologic toxicity, including ICANS.

**Infections:** LYNOZYFIC can cause serious, life-threatening, or fatal infections. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 38% and fatal infections in 4%. The most common serious infection reported ( $\geq 10\%$ ) were pneumonia and sepsis. Two cases of progressive multifocal leukoencephalopathy (PML) occurred in patients receiving LYNOZYFIC.

Monitor patients for signs and symptoms of infection and immunoglobulin levels prior to and during treatment with LYNOZYFIC and treat appropriately. Administer prophylactic antimicrobials, antibiotics, antifungals, antivirals, vaccines, and subcutaneous or intravenous immunoglobulin (IVIG) according to guidelines, including prophylaxis for PJP and herpesviruses. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity of the infection.

**Neutropenia:** LYNOZYFIC can cause neutropenia and febrile neutropenia. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, decreased neutrophil count occurred in 62% of patients with Grade 3 or 4 decreased neutrophil count in 47%. Febrile neutropenia occurred in 8% of patients.

Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local guidelines. Monitor patients with neutropenia for signs of infection. Withhold LYNOZYFIC based on severity.

**Hepatotoxicity:** LYNOZYFIC can cause hepatotoxicity. In LINKER-MM1, elevated ALT occurred in 46% of patients, with Grade 3 or 4 ALT elevation occurring in 6%; elevated AST occurred in 61% of patients, with Grade 3 or 4 AST elevation occurring in 10% of patients who received the recommended dose. Grade 3 or 4 total bilirubin elevations occurred in 1.7% of patients. Liver enzyme elevation can occur with or without concurrent CRS.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity.

**Embryo-Fetal Toxicity:** Based on its mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LYNOZYFIC and for 3 months after the last dose.

### Adverse Reactions

The most common adverse reactions ( $\geq 20\%$ ) are musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea. The most common Grade 3 or 4 laboratory abnormalities ( $\geq 30\%$ ) are decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.

### Use in Specific Populations

**Lactation:** Advise not to breastfeed.

**Please see accompanying full Prescribing Information, including Boxed WARNING, for LYNOZYFIC.**

**Reference:** LYNOZYFIC™ (linvoseltamab-gcpt) full U.S. prescribing information. Regeneron Pharmaceuticals, Inc.

All trademarks are property of their respective owners.

**REGENERON**®

© 2026 Regeneron Pharmaceuticals, Inc. All rights reserved.  
777 Old Saw Mill River Road, Tarrytown, NY 10591  
US.LYN.26.01.0013 03/26

 **LYNOZYFIC**™  
(linvoseltamab-gcpt) Injection  
5mg | 200mg